AndroGel Adolescent (12, 17) Monitoring: A Complete Clinical Guide

What Is AndroGel and Why Is It Used in Adolescents?

AndroGel delivers testosterone transdermally as either a 1% gel (12.5 mg or 25 mg per packet) or a 1.62% gel (20.25 mg or 40.5 mg per actuation). In adolescent males aged 12, 17, prescribers use it off-label to treat confirmed hypogonadism, constitutional delay of puberty unresponsive to watchful waiting, or Klinefelter syndrome (47,XXY). The FDA approved AndroGel for adult male hypogonadism; adolescent use requires explicit shared decision-making and documented informed consent from both the patient and a guardian. [1]

Male hypogonadism in adolescence means the testes cannot produce enough testosterone to drive pubertal progression. Klinefelter syndrome, the most common sex-chromosome disorder at roughly 1 in 500, 650 live male births, accounts for a substantial portion of adolescent hypogonadism cases. [2] Without intervention, boys may experience arrested puberty, reduced bone mineral density, impaired linear growth potential, and psychosocial distress. Testosterone replacement therapy (TRT), when monitored correctly, can restore normal pubertal tempo.

The T-Trials, a coordinated set of trials published in the New England Journal of Medicine (N=790 older men), confirmed that topical testosterone raises serum T reliably into the normal range with daily application, establishing the pharmacokinetic rationale that informs adolescent dosing extrapolation. [3] Adolescent-specific controlled data remain limited, which is exactly why structured monitoring is non-negotiable.

How Is AndroGel Dosed in Adolescents Aged 12, 17?

Dosing in adolescents starts low and rises slowly. The most common initiation is AndroGel 1.62% at 20.25 mg (one pump actuation) applied to the upper arm or shoulder once daily. Some pediatric endocrinologists prefer testosterone enanthate injections for early puberty induction because the dose is easier to control, but transdermal gel is preferred when a more gradual, physiologic rise is desired. [4]

Serum testosterone is checked 2 hours after application at the 2-week mark. If the reading falls below 300 ng/dL, the dose is increased by one pump (20.25 mg) to a total of 40.5 mg/day. The target range for adolescents is 300 to 700 ng/dL, which mimics mid-pubertal to early-adult normal. Exceeding 700 ng/dL consistently is a signal to reduce the dose, not to continue at the same level. [5]

Gel should be applied to clean, dry, intact skin on the upper arm or shoulder. Application to the genitals is contraindicated. Patients must wash hands thoroughly after application and cover the site with clothing before contact with others. [1]

Serum Testosterone Monitoring Schedule

Consistent lab timing is the single most controllable variable in adolescent testosterone monitoring. Draws taken at random times of day after gel application produce readings that vary by as much as 40%, making dose decisions unreliable. [6]

The recommended blood draw protocol is:

• Week 2: Serum total testosterone drawn 2 hours post-application. Use this to confirm absorption and establish a patient-specific peak.
• Month 3: Serum total testosterone plus LH, FSH, and SHBG. LH and FSH help differentiate primary from secondary hypogonadism and confirm whether endogenous production is suppressed.
• Month 6 and every 6 months thereafter: Repeat serum T at the same post-application interval used at week 2. Add free testosterone if total T is within range but symptoms persist.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We recommend measuring serum testosterone levels to ensure that testosterone concentrations are in the mid-normal range." [5] Adolescents metabolize topical testosterone at rates that differ from adults because of higher skin turnover and greater surface-area-to-body-mass ratios, so the same pump dose can produce serum levels 15 to 25% higher than in an adult of similar weight. [7]

Bone Age and Linear Growth Monitoring

Bone age is the single most important safety parameter in adolescent TRT. Excess androgens accelerate epiphyseal fusion, permanently limiting final adult height. A boy who fuses his growth plates at bone age 16 instead of 18 loses an estimated 2 to 5 cm of final height. [8]

Bone age is assessed with a plain radiograph of the left hand and wrist, read against the Greulich and Pyle atlas. The schedule is:

• Baseline before first dose
• Every 6 months during active treatment
• At any point if height velocity drops unexpectedly

Height velocity should be recorded at each clinic visit. Normal mid-puberty height velocity is 7 to 12 cm/year. A fall below 4 cm/year during active TRT, or a bone age that is advancing more than 1.5 years per calendar year, should prompt a dose reduction or a temporary treatment pause. [9]

The Pediatric Endocrine Society recommends that providers "monitor bone maturation every 6 months in patients receiving androgen therapy during the pubertal years." [9] Growth plates that are already fused (bone age at or above 16 to 17 years) make this parameter less urgent, but the radiograph at baseline is still required to document the starting point.

Hematocrit and Erythrocytosis Monitoring

Testosterone stimulates erythropoiesis. In adults, erythrocytosis (hematocrit above 54%) is the most common laboratory adverse event in TRT, occurring in roughly 11% of injectable TRT users and 3 to 4% of transdermal TRT users. [10] Adolescents are not exempt. The lower erythrocytosis rate with transdermal gel is one reason some pediatric endocrinologists prefer it over injectable testosterone in this age group.

Monitoring schedule:

• Baseline complete blood count (CBC) before first dose
• Hematocrit at month 3
• Hematocrit every 6 to 12 months during stable therapy

If hematocrit exceeds 52% in an adolescent, the prescriber should hold the next dose and recheck in 4 weeks. A confirmed reading above 54% requires a dose reduction. Therapeutic phlebotomy is rarely needed in adolescent transdermal gel users but remains an option if hematocrit does not normalize after dose reduction. [5]

Adolescents with baseline hemoglobin above the 97th percentile for age, or with a personal or family history of polycythemia vera, require extra caution and more frequent CBC checks. [10]

Lipid Panel and Cardiovascular Monitoring

Exogenous testosterone lowers HDL cholesterol and can raise LDL. A meta-analysis of 51 randomized controlled trials (N=5,700) found that testosterone reduced HDL by a mean of 0.49 mmol/L (roughly 19 mg/dL) and total cholesterol by 0.29 mmol/L. [11] These changes are dose-dependent and more pronounced with supraphysiologic levels.

For adolescents, a fasting lipid panel should be obtained at baseline and repeated at 6 months. Annual lipid checks are sufficient during stable therapy, provided serum testosterone remains within the 300 to 700 ng/dL target. Adolescents with pre-existing dyslipidemia, obesity (BMI >30 kg/m2), or a first-degree relative with premature cardiovascular disease require a lipid check at every 3-month visit. [11]

Blood pressure should be recorded at each visit. Testosterone modestly raises both systolic and diastolic blood pressure in some patients. A systolic reading above 130 mmHg on two separate visits is an indication for lifestyle counseling and possible dose review. [12]

Bone Mineral Density

Hypogonadism in adolescence reduces bone mineral density (BMD). Boys with Klinefelter syndrome average a BMD Z-score roughly 0.5, 1.0 SD below age-matched controls at diagnosis. [13] Testosterone replacement improves BMD by stimulating osteoblast activity, but the improvement takes 12 to 24 months to appear on dual-energy X-ray absorptiometry (DXA).

A baseline DXA scan of the lumbar spine and total hip is recommended for all adolescents beginning TRT, particularly those with Klinefelter syndrome or a history of fragility fractures. Repeat DXA at 24 months of therapy documents the treatment response. [13] Normal adolescent DXA interpretation uses Z-scores (age- and sex-matched), not T-scores, which are reserved for post-menopausal women and men over 50. [14]

Mental Health and Psychosocial Monitoring

Testosterone influences mood, aggression, and impulse control. Adolescence is already a period of significant neurobiological change, and adding exogenous testosterone may amplify mood variability in some patients. [15] It can also improve mood in boys with hypogonadism who present with depression, fatigue, and social withdrawal before treatment.

Every clinical visit should include a structured mental-health screen using the Patient Health Questionnaire for Adolescents (PHQ-A) or the Columbia Suicide Severity Rating Scale (C-SSRS) in higher-risk patients. The framework below summarizes how to act on the results:

• PHQ-A score 0, 4: Continue current dose; re-screen at next scheduled visit.
• PHQ-A score 5, 9: Counsel patient and guardian; consider referral to behavioral health. Continue current dose unless other stopping signals are present.
• PHQ-A score 10 or above: Immediate behavioral health referral. Reassess whether TRT dose or timing may be contributing. Do not automatically discontinue TRT, as abrupt cessation can worsen depression in hypogonadal boys.

Behavioral complaints, including increased irritability or verbal aggression reported by parents, should trigger a dose check before attributing symptoms to behavioral causes. A serum testosterone above 700 ng/dL at the standard 2-hour post-application draw often explains these reports. [15]

Skin Transfer and Household Safety

Secondary exposure to testosterone gel is a documented safety concern. The FDA issued a black-box warning for testosterone gel products after reports of virilization in young children exposed through skin contact with treated adults. [1] In a household with an adolescent patient, siblings and younger children are at risk if application and coverage protocols are not followed.

Instruct patients and guardians on the following at every visit:

• Apply gel to the upper arm or shoulder only, never the chest or abdomen where clothing contact with others is more likely.
• Cover the application site with clothing before any physical contact with household members.
• Wash the application site with soap and water before swimming, bathing, or contact sports.
• Store unused gel packets and pumps out of reach of younger children.

A 2010 FDA safety communication documented 20 pediatric cases of secondary testosterone exposure from topical gel on adults, with signs including premature pubic hair, clitoral or penile enlargement, and advanced bone age. [16] These outcomes are entirely preventable with consistent application hygiene.

Monitoring for Testosterone Suppression of the Hypothalamic-Pituitary Axis

Exogenous testosterone suppresses LH and FSH through negative feedback on the hypothalamic-pituitary axis. In adolescents who retain some endogenous testicular function, this suppression may delay or prevent spontaneous puberty progression if TRT is discontinued. [17] This is a particular concern in boys with constitutional delay of puberty, where the goal is to prime puberty rather than replace it permanently.

LH and FSH should be measured at month 3 and at 12 months. If LH and FSH are both undetectable at 12 months and the clinical intention is to transition to endogenous puberty, a 3-month treatment pause under close monitoring may clarify whether the axis recovers. Boys with primary hypogonadism (Klinefelter syndrome, anorchia) will not recover endogenous function and require lifelong TRT, making axis monitoring less relevant for dosing decisions but still useful for identifying compliance patterns. [17]

A study published in the Journal of Clinical Endocrinology and Metabolism (N=47 adolescents with Klinefelter syndrome) found that testosterone therapy initiated before age 14 was associated with improved verbal memory scores but did not suppress the hypothalamic-pituitary axis recovery to any greater degree than therapy initiated later, suggesting timing matters for cognitive outcomes but not for endocrine axis preservation. [18]

Transition Planning: Moving from Adolescent to Adult Care

Adolescents on long-term TRT need a structured transition plan before their 18th birthday. Without a handoff protocol, patients frequently experience gaps in care, inappropriate dose changes, or loss of monitoring records. The American Academy of Pediatrics recommends that transition planning begin by age 14 for all youth with chronic health conditions requiring ongoing medication. [19]

For adolescents on AndroGel, transition planning includes:

• A summary letter from the pediatric endocrinologist documenting the diagnosis, all prior testosterone levels, bone-age series results, DXA findings, and current dose.
• Identification of an adult endocrinologist or urologist experienced in male hypogonadism before the final pediatric visit.
• A 6-month overlap period where both providers communicate directly.
• Patient education on self-monitoring: recognizing symptoms of over- or under-replacement, correct application technique, and when to seek urgent care.

At the transition point, the adult provider should reconfirm the diagnosis with a fresh morning serum testosterone draw (before any gel application that day) and reassess whether the gel formulation remains the preferred delivery route. Some patients prefer injections or pellets in adulthood for convenience. [20]

Summary Monitoring Table

The following schedule consolidates all monitoring parameters for a prescriber or care coordinator managing an adolescent on AndroGel. [5, 9, 10, 13]

| Parameter | Baseline | Week 2 | Month 3 | Month 6 | Every 6 Mo | Every 12 Mo | |---|---|---|---|---|---|---| | Serum total testosterone | Yes | Yes | Yes | Yes | Yes | | | LH, FSH, SHBG | Yes | | Yes | | Yes | | | Hematocrit / CBC | Yes | | Yes | | Yes | | | Fasting lipid panel | Yes | | | Yes | | Yes | | Blood pressure | Yes | | Yes | Yes | Yes | | | Bone-age radiograph | Yes | | | Yes | Yes | | | Height and weight | Yes | | Yes | Yes | Yes | | | DXA scan | Yes | | | | | Every 24 Mo | | PHQ-A mental health | Yes | | Yes | Yes | Yes | |

A serum testosterone level of 400 ng/dL drawn 2 hours after application, on a consistent schedule, with a stable hematocrit below 50%, bone age advancing no faster than chronological age, and a PHQ-A score below 5, represents a well-monitored adolescent patient on AndroGel therapy.